The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, but its position within the broader sector now presents questions about potential yields . Copycat versions are diminishing market share, leading to concerns that betting on companies closely tied to Viagra's former influence could be a dangerous strategy,